Becton, Dickinson and Company (BDX)
After hours:
| Previous close | 233.44 |
| Open | 232.81 |
| Bid | 234.47 x 1100 |
| Ask | 234.56 x 1100 |
| Day's range | 232.06 - 234.82 |
| 52-week range | 229.40 - 287.32 |
| Volume | |
| Avg. volume | 1,339,604 |
| Market cap | 67.75B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 53.66 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.80 (1.63%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
BD to Present at Bank of America Securities Health Care Conference 2024
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference 2024 on Tuesday, May 14, 2024 at 11:00 am Eastern Time.
- PR Newswire
BD Named a Best Employer for Excellence in Employee Well-Being
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will receive the Business Group on Health "Best Employers: Excellence in Health & Well-being Award" for its commitment to advancing employee well-being through comprehensive and innovative benefits and initiatives.
- PR Newswire
BD Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments.
